GIGA-CARBON-NEUTRALITY
11.11.2021 09:54:11 CET | Business Wire | Press release
Giga Carbon Neutrality (GCN), the clean trucking and technology company, today unveiled a comprehensive range of zero-emission commercial vehicles that it plans to bring to market over the next two years – answering the call from the world’s transportation and logistics operators for a fleet of different options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005555/en/
GCN will launch 21 different battery-electric and hydrogen fuel-cell powered vehicles by the end of 2023. GCN’s portfolio is configurable to a wide range of commercial use cases and includes a tractor unit, buses and last-mile logistics vehicles. The company’s first prototype hydrogen-fueled tractor unit is currently undergoing advanced road and usability trials in China.
GCN designs its vehicles at a state-of-the-art research and development centre located in Hangzhou , China. GCN has developed its own proprietary hydrogen fuel-cell technology and will source batteries from leading manufacturers initially.
The GCN vehicles are manufactured using lightweight stainless steel and composite materials to improve safety and deliver reductions in weight and energy consumption of at least 10 per cent. The bodies of GCN vehicles are designed to last for 20 years, significantly longer than vehicles from other providers on the market.
GCN is working with public and private sector partners to provide clean energy storage, charging and refueling infrastructure, as well as specialist financing to support the adoption of its zero-emission commercial vehicles globally.
Marty Wade, CEO at Giga Carbon Neutrality, comments: “We are thrilled to give the world its first look at the future of zero-emission commercial transportation.”
“GCN is enabling a carbon-neutral future for some of the world’s most energy-intensive industries, with clean energy vehicles, new technologies and a fueling ecosystem to make running clean, reliable vehicle fleets easy for commercial transportation companies.”
Giga’s initial fleet of zero-emission commercial vehicles
Several GCN vehicles are available to order immediately, with delivery times of between three and 12 months. The company’s initial range includes:
- The GCN Hydrogen Tractor: A 44-tonne hydrogen fuel-cell truck with a top speed of 90 kph and 580 km range before refueling. Streamlined to minimise wind-resistance, GCN’s ‘heavy truck’ features an ergonomic cab design and a range of intelligent safety systems such as driver fatigue warning systems as standard. A prototype of this vehicle is already on the road in China.
- The GCN City Bus: A 12-metre transit bus for urban public transport. Capable of carrying up to 95 passengers, GCN’s city bus has a 350 km range on a battery-electric power train and features a monocoque body and collision protection structure offering improved safety for the driver and passengers. This vehicle is designed to meet European Union approved standards for use in its 27 member states.
- The GCN Pure Electric Minibus: A 6.9-metre battery-electric minibus with an ultra-long wheelbase and flat floor structure to provide capacity for up to 13 passengers. GCN’s minibuses have a 240 km range on a single charge and are already being used on the road in Hong Kong. Autonomous vehicles can also be developed based on this platform.
- The GCN Electric Logistics Vehicle: An 8-tonne battery-electric truck to support last-mile logistics in urban and rural areas. GCN’s logistics truck has a spacious loading area, can be configured to customer needs and can cover 250 km on a single charge.
About Giga Carbon Neutrality (www.gigacarbonneutrality.com )
Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
